Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
종목 코드 DYAI
회사 이름Dyadic International Inc
상장일Nov 05, 2004
CEOMr. Mark A. Emalfarb
직원 수6
유형Ordinary Share
회계 연도 종료Nov 05
주소1044 North U.S. Highway One
도시JUPITER
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호33477
전화15617438333
웹사이트https://dyadic.com/
종목 코드 DYAI
상장일Nov 05, 2004
CEOMr. Mark A. Emalfarb
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음